SEC Form 4 · accession 0001209191-17-041875
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark S. Levine
Officer — SVP & General Counsel
Period of report
Jun 26, 2017
Accepted (ET)
Jun 26, 2017 · 9:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $21.74 | Jun 26, 2017 | A | 125,000 | A | — | Jun 25, 2027 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option shall vest on June 26, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following June 26, 2018, so that all of the shares subject to the option shall be vested after June 26, 2021.